Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine butylbromide versus drotaverine versus placebo for shortening the active phase of labour
PACTR202607885056142Phase 4Not yet recruiting
- Sponsor
- Kenechukwu Obi
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hyoscine butylbromide, drotaverine and Placebo-COD Research Private Ltd (3 arms), sponsored by Kenechukwu Obi. Primary endpoint: Mean duration of the active phase of labour. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
hyoscine butylbromidedrotaverinePlacebo-COD Research Private Ltd
Beyond the preview
Go deeper on PACTR202607885056142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607885056142.